Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment

Bayer, V. An overview of monoclonal antibodies. Semin. Oncol. Nurs., 2019, 35(5), 150972.
[http://dx.doi.org/10.1016/j.soncn.2019.08.006]

Breedveld, F.C. Therapeutic monoclonal antibodies. Lancet, 2000, 355(9205), 735-740.
[http://dx.doi.org/10.1016/S0140-6736(00)01034-5] [PMID: 10703815]

Nelson, P.N.; Reynolds, G.M.; Waldron, E.E.; Ward, E.; Giannopoulos, K.; Murray, P.G. Monoclonal antibodies. Mol. Pathol., 2000, 53(3), 111-117.
[http://dx.doi.org/10.1136/mp.53.3.111] [PMID: 10897328]

Zahavi, D.; Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies, 2020, 9(3), 34.
[http://dx.doi.org/10.3390/antib9030034] [PMID: 32698317]

Shuptrine, C.W.; Surana, R.; Weiner, L.M. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol., 2012, 22(1), 3-13.
[http://dx.doi.org/10.1016/j.semcancer.2011.12.009] [PMID: 22245472]

Mahmuda, A.; Bande, F.; Kadhim Al-Zihiry, K.J.; Abdulhaleem, N.; Majid, R.A.; Hamat, R.A.; Abdullah, W.O.; Unyah, Z. Monoclonal antibodies: A review of therapeutic applications and future prospects. Trop. J. Pharm. Res., 2017, 16(3), 713-722.
[http://dx.doi.org/10.4314/tjpr.v16i3.29]

Coulson, A.; Levy, A.; Gossell-Williams, M. Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations. West Indian Med. J., 2014, 63(6), 650-654.
[PMID: 25803383]

Cui, Y.; Cui, P.; Chen, B.; Li, S.; Guan, H. Monoclonal antibodies: Formulations of marketed products and recent advances in novel delivery system. Drug Dev. Ind. Pharm., 2017, 43(4), 519-530.
[http://dx.doi.org/10.1080/03639045.2017.1278768] [PMID: 28049357]

Roskos, L.K.; Davis, C.G.; Schwab, G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res., 2004, 61(3), 108-120.
[http://dx.doi.org/10.1002/ddr.10346]

Dang, M.N.; Hoover, E.C.; Scully, M.A.; Sterin, E.H.; Day, E.S. Antibody nanocarriers for cancer management. Curr. Opin. Biomed. Eng., 2021, 19(100295), 1-9.
[PMID: 34423177]

Pento, J.T. Monoclonal antibodies for the treatment of cancer. Anticancer Res., 2017, 37(11), 5935-5939.
[PMID: 29061772]

Kimiz-Gebologlu, I.; Gulce-Iz, S.; Biray-Avci, C. Monoclonal antibodies in cancer immunotherapy. Mol. Biol. Rep., 2018, 45(6), 2935-2940.
[http://dx.doi.org/10.1007/s11033-018-4427-x] [PMID: 30311129]

Hafeez, U.; Gan, H.K.; Scott, A.M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol., 2018, 41, 114-121.
[http://dx.doi.org/10.1016/j.coph.2018.05.010] [PMID: 29883853]

Azamjah, N.; Soltan-Zadeh, Y.; Zayeri, F. Global trend of breast cancer mortality rate: A 25-year study. Asian Pac. J. Cancer Prev., 2019, 20(7), 2015-2020.
[http://dx.doi.org/10.31557/APJCP.2019.20.7.2015] [PMID: 31350959]

Watkins, E.J. Overview of breast cancer. JAAPA, 2019, 32(10), 13-17.
[http://dx.doi.org/10.1097/01.JAA.0000580524.95733.3d] [PMID: 31513033]

Breast cancer a World Health Organization report.. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer (Accessed on 12 April 2022)

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]

Sharma, G.N.; Dave, R.; Sanadya, J.; Sharma, P.; Sharma, K.K. Various types and management of breast cancer: An overview. J. Adv. Pharm. Technol. Res., 2010, 1(2), 109-126.
[PMID: 22247839]

Liu, M.; Yu, X.; Chen, Z.; Yang, T.; Yang, D.; Liu, Q.; Du, K.; Li, B.; Wang, Z.; Li, S.; Deng, Y.; He, N. Aptamer selection and applications for breast cancer diagnostics and therapy. J. Nanobiotechnol., 2017, 15(1), 81.
[http://dx.doi.org/10.1186/s12951-017-0311-4] [PMID: 29132385]

Akram, M.; Iqbal, M.; Daniyal, M.; Khan, A.U. Awareness and current knowledge of breast cancer. Biol. Res., 2017, 50(1), 33.
[http://dx.doi.org/10.1186/s40659-017-0140-9] [PMID: 28969709]

Helmi, O.; Elshishiny, F.; Mamdouh, W. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. Int. J. Biol. Macromol., 2021, 184, 325-338.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.06.014] [PMID: 34119547]

Heim, E.; Valach, L.; Schaffner, L. Coping and psychosocial adaptation: Longitudinal effects over time and stages in breast cancer. Psychosom. Med., 1997, 59(4), 408-418.
[http://dx.doi.org/10.1097/00006842-199707000-00011] [PMID: 9251161]

Bednarek, A.K.; Sahin, A.; Brenner, A.J.; Johnston, D.A.; Aldaz, C.M. Analysis of telomerase activity levels in breast cancer: Positive detection at the in situ breast carcinoma stage. Clin. Cancer Res., 1997, 3(1), 11-16.
[PMID: 9815531]

Segal, R.; Evans, W.; Johnson, D.; Smith, J.; Colletta, S.; Gayton, J.; Woodard, S.; Wells, G.; Reid, R. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of a randomized controlled trial. J. Clin. Oncol., 2001, 19(3), 657-665.
[http://dx.doi.org/10.1200/JCO.2001.19.3.657] [PMID: 11157015]

Moran, M.S.; Schnitt, S.J.; Giuliano, A.E.; Harris, J.R.; Khan, S.A.; Horton, J.; Klimberg, S.; Chavez-MacGregor, M.; Freedman, G.; Houssami, N.; Morrow, M. Society of surgical oncology-american society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2014, 88(3), 553-564.

Jacquillat, C.; Weil, M.; Baillet, F.; Borel, C.; Auclerc, G.; De Maublanc, M.A.; Housset, M.; Forget, G.; Thill, L.; Soubrane, C.; Khayat, D. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer, 1990, 66(1), 119-129.
[http://dx.doi.org/10.1002/1097-0142(19900701)66:1<119:AID-CNCR2820660122>3.0.CO;2-3] [PMID: 2112976]

Neuman, H.B.; Morrogh, M.; Gonen, M.; Van Zee, K.J.; Morrow, M.; King, T.A. Stage IV breast cancer in the era of targeted therapy. Cancer, 2010, 116(5), 1226-1233.
[http://dx.doi.org/10.1002/cncr.24873] [PMID: 20101736]

Nielsen, D.L.; Kümler, I.; Palshof, J.A.E.; Andersson, M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast, 2013, 22(1), 1-12.
[http://dx.doi.org/10.1016/j.breast.2012.09.008] [PMID: 23084121]

Mohit, E.; Hashemi, A.; Allahyari, M. Breast cancer immunotherapy: Monoclonal antibodies and peptide-based vaccines. Expert Rev. Clin. Immunol., 2014, 10(7), 927-961.
[http://dx.doi.org/10.1586/1744666X.2014.916211] [PMID: 24867051]

Karly, P. Trastuzumab a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Adis Drug Evaluation., 2010, 70(2), 215-239.

Gillian, M. Keating, Pertuzumab in the first-line treatment of HER2-positive metastatic breast cancer. Adis Drug Profile., 2012, 72(3), 353-360.

Boyiadzis, M.; Foon, K.A. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther., 2008, 8(8), 1151-1158.
[http://dx.doi.org/10.1517/14712598.8.8.1151] [PMID: 18613766]

Kiewe, P.; Thiel, E. Ertumaxomab: A trifunctional antibody for breast cancer treatment. Expert Opin. Investig. Drugs, 2008, 17(10), 1553-1558.
[http://dx.doi.org/10.1517/13543784.17.10.1553] [PMID: 18808314]

Adams, S.; Diamond, J.R.; Hamilton, E.; Pohlmann, P.R.; Tolaney, S.M.; Chang, C.W.; Zhang, W.; Iizuka, K.; Foster, P.G.; Molinero, L.; Funke, R.; Powderly, J. Atezolizumab Plus nab-Paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-Year survival follow-up a phase 1b clinical trial. JAMA Oncol., 2019, 5(3), 334-342.
[http://dx.doi.org/10.1001/jamaoncol.2018.5152] [PMID: 30347025]

Nami, B.; Maadi, H.; Wang, Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers, 2018, 10(10), 342.
[http://dx.doi.org/10.3390/cancers10100342] [PMID: 30241301]

Greg, L. Trastuzumab a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Adis Drug Evaluation., 2006, 66(4), 449-475.

Hudis, C.A. Trastuzumab--mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357(1), 39-51.
[http://dx.doi.org/10.1056/NEJMra043186] [PMID: 17611206]

Levêque, D.; Gigou, L.; Bergerat, J. Clinical pharmacology of trastuzumab. Curr. Clin. Pharmacol., 2008, 3(1), 51-55.
[http://dx.doi.org/10.2174/157488408783329931] [PMID: 18690878]

Annelies, H.; Boekhout, J.H.; Beijnen, H.M. Trastuzumab. Oncologist, 2011, 16, 800-810.

McKeage, K.; Perry, C.M. Trastuzumab. Drugs, 2002, 62(1), 209-243.
[http://dx.doi.org/10.2165/00003495-200262010-00008] [PMID: 11790161]

Bader, A.A.; Schlembach, D.; Tamussino, K.F.; Pristauz, G.; Petru, E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol., 2007, 8(1), 79-81.
[http://dx.doi.org/10.1016/S1470-2045(06)71014-2]

Baselga, J. Clinical trials of Herceptin® (trastuzumab). Eur. J. Cancer, 2001, 37(1), 18-24.
[http://dx.doi.org/10.1016/S0959-8049(00)00404-4] [PMID: 11342196]

Vogel, C.L.; Melody, A.C.; Debu, T.; John, C.; Gutheil; Lyndsay, N.H.; Louis, F.; Dennis, J.S.; Mureen, M.; Michael, P. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2 overexpressing metaststic breast cancer. J. Clin. Oncol., 2002, 120(3), 719-726.
[http://dx.doi.org/10.1200/JCO.2002.20.3.719] [PMID: 11821453]

Jhaveri, K.; Esteva, F.J. Pertuzumab in the treatment of HER2+ breast cancer. J. Natl. Compr. Canc. Netw., 2014, 12(4), 591-598.
[http://dx.doi.org/10.6004/jnccn.2014.0059] [PMID: 24717573]

Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res., 2009, 69(24), 9330-9336.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4597] [PMID: 19934333]

Bernard-Marty, C.; Lebrun, F.; Awada, A.; Piccart, M.J. Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions. Drugs, 2006, 66(12), 1577-1591.
[http://dx.doi.org/10.2165/00003495-200666120-00004] [PMID: 16956305]

Chee, M. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm. Res., 2006, 23(6), 1275-1284.

Attard, G.; Kitzen, J.; Blagden, S.P.; Fong, P.C.; Pronk, L.C.; Zhi, J.; Zugmaier, G.; Verweij, J.; De Bono, J.S.; De Jonge, M. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br. J. Cancer, 2007, 97(10), 1338-1343.
[PMID: 18000498]

Barthélémy, P.; Leblanc, J.; Goldbarg, V.; Wendling, F.; Kurtz, J.E. Pertuzumab: Development beyond breast cancer. Anticancer Res., 2014, 34(4), 1483-1491.
[PMID: 24692675]

Capelan, M.; Pugliano, L.; De Azambuja, E.; Bozovic, I.; Saini, K.S.; Sotiriou, C.; Loi, S.; Piccart-Gebhart, M.J. Pertuzumab: New hope for patients with HER2-positive breast cancer. Ann. Oncol., 2013, 24(2), 273-282.
[http://dx.doi.org/10.1093/annonc/mds328] [PMID: 22910839]

Baselga, J.; Cortés, J.; Kim, S.B.; Im, S.A.; Hegg, R.; Im, Y.H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; Clark, E.; Benyunes, M.C.; Ross, G.; Swain, S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med., 2012, 366(2), 109-119.
[http://dx.doi.org/10.1056/NEJMoa1113216] [PMID: 22149875]

Gianni, L.; Lladó, A.; Bianchi, G.; Cortes, J.; Kellokumpu-Lehtinen, P.L.; Cameron, D.A.; Miles, D.; Salvagni, S.; Wardley, A.; Goeminne, J.C.; Hersberger, V.; Baselga, J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol., 2010, 28(7), 1131-1137.
[http://dx.doi.org/10.1200/JCO.2009.24.1661] [PMID: 20124183]

Nielsen, D.L.; Andersson, M.; Kamby, C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat. Rev., 2009, 35(2), 121-136.
[http://dx.doi.org/10.1016/j.ctrv.2008.09.003] [PMID: 19008049]

Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57(20), 4593-4599.
[PMID: 9377574]

Wang, Y.; Fei, D.; Vanderlaan, M.; Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7(4), 335-345.
[http://dx.doi.org/10.1007/s10456-004-8272-2] [PMID: 15886877]

Gordon, M.S.; Margolin, K.; Talpaz, M.; Sledge, G.W., Jr; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D.C. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol., 2001, 19(3), 843-850.
[http://dx.doi.org/10.1200/JCO.2001.19.3.843] [PMID: 11157038]

Lyseng-Williamson, K.A.; Robinson, D.M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs, 2006, 20(3), 193-195.
[http://dx.doi.org/10.2165/00063030-200620030-00007] [PMID: 16724868]

Hamilton, E.P.; Blackwell, K.L. Safety of bevacizumab in patients with metastatic breast cancer. Oncology, 2011, 80(5-6), 314-325.
[http://dx.doi.org/10.1159/000328757] [PMID: 21778772]

Alexander, T.; Barrière, J.; François, E.; Follana, P. Bevacizumab: A dose review. Crit. Rev. Oncol. Hematol., 2015, 94(3), 311-322.
[http://dx.doi.org/10.1016/j.critrevonc.2015.01.012] [PMID: 25703583]

Rugo, H.S. Bevacizumab in the treatment of breast Cancer: Rationale and current data. Oncologist, 2004, 9(S1), 43-49.
[http://dx.doi.org/10.1634/theoncologist.9-suppl_1-43] [PMID: 15178815]

Zeidler, R.; Reisbach, G.; Wollenberg, B. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol., 1999, 163(3), 1246-1252.
[PMID: 10415020]

Riesenberg, R.; Buchner, A.; Pohla, H.; Lindhofer, H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J. Histochem. Cytochem., 2001, 49(7), 911-917.
[http://dx.doi.org/10.1177/002215540104900711] [PMID: 11410615]

Riechelmann, H.; Wiesneth, M.; Schauwecker, P. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Cancer Immunol. Immunother., 2007, 56(9), 1397-1406.
[http://dx.doi.org/10.1007/s00262-007-0283-6] [PMID: 17273869]

Zeidler, R.; Mysliwietz, J.; Csanady, M.; Walz, A.; Ziegler, I.; Schmitt, B.; Wollenberg, B.; Lindhofer, H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br. J. Cancer, 2000, 83(2), 261-266.
[http://dx.doi.org/10.1054/bjoc.2000.1237] [PMID: 10901380]

Haense, N.; Atmaca, A.; Pauligk, C.; Steinmetz, K.; Marmé, F.; Haag, G.M.; Rieger, M.; Ottmann, O.G.; Ruf, P.; Lindhofer, H.; Al-Batran, S-E. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer, 2016, 16, 420.
[http://dx.doi.org/10.1186/s12885-016-2449-0] [PMID: 27387446]

Cardoso, F.; Dirix, L.; Conte, P.F.; Semiglazov, V.; de Placido, S.; Jaeger, M.; Mueller, C.; Eschenbach, B.; Klunker, D.; Lindhofer, H.; Cortes, J. Abstract P3-14-21: Phase II study of single agent trifunctional antibody ertumaxomab (anti-HER-2 and anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC). Cancer Res., 2010, 70(24_Supplement), P3-14-21.
[http://dx.doi.org/10.1158/0008-5472.SABCS10-P3-14-21]

Kiewe, P.; Hasmüller, S.; Kahlert, S.; Heinrigs, M.; Rack, B.; Marmé, A.; Korfel, A.; Jäger, M.; Lindhofer, H.; Sommer, H.; Thiel, E.; Untch, M.; Untch, H. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res., 2006, 12(10), 3085-3091.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2436] [PMID: 16707606]

Jäger, M.; Schoberth, A.; Ruf, P.; Hess, J.; Lindhofer, H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res., 2009, 69(10), 4270-4276.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2861] [PMID: 19435924]

Reddy, S.M.; Carroll, E.; Nanda, R. Atezolizumab for the treatment of breast cancer. Expert Rev. Anticancer Ther., 2020, 20(3), 151-158.
[http://dx.doi.org/10.1080/14737140.2020.1732211] [PMID: 32067545]

Roy, S.; Soria, J-C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
[http://dx.doi.org/10.1038/nature14011] [PMID: 25428504]

Marchand, M.; Claret, L.; Eppler, S.; Ruppel, J.; Abidoye, O.; Teng, S.L.; Lin, W-T.; Dayog, S.; Bruno, R.; Jin, J.; Girish, S. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin. Pharmacol. Ther., 2017, 102(2), 305-312.
[http://dx.doi.org/10.1002/cpt.587] [PMID: 27981577]

Heimes, A.S.; Schmidt, M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin. Investig. Drugs, 2019, 28(1), 1-5.
[http://dx.doi.org/10.1080/13543784.2019.1552255] [PMID: 30474425]

Basile, D.; Pelizzari, G.; Vitale, M.G.; Lisanti, C.; Cinausero, M.; Iacono, D.; Puglisi, F. Atezolizumab for the treatment of breast cancer. Expert Opin. Biol. Ther., 2018, 18(5), 595-603.
[http://dx.doi.org/10.1080/14712598.2018.1469619] [PMID: 29690797]

Henze, A.T.; Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest., 2016, 126(10), 3672-3679.
[http://dx.doi.org/10.1172/JCI84427] [PMID: 27482883]

Thomas, A.; Teicher, B.A.; Hassan, R. Antibody- drug conjugates for cancer therapy. Lancet Oncol., 2016, 17(6), e254-e262.
[http://dx.doi.org/10.1016/S1470-2045(16)30030-4] [PMID: 27299281]

Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol., 2009, 157(2), 220-233.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x] [PMID: 19459844]

Jackson, D.; Atkinson, J.; Guevara, C.I.; Zhang, C.; Kery, V.; Moon, S.; Virata, C.; Yang, P.; Lowe, C.; Pinkstaff, J.; Cho, H.; Knudsen, N.; Manibusan, A.; Tian, F.; Sun, Y.; Lu, Y.; Sellers, A.; Jia, X-C.; Joseph, I.; Anand, B.; Morrison, K.; Pereira, D.S.; Stover, D. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS One, 2014, 9(1), e83865.
[http://dx.doi.org/10.1371/journal.pone.0083865] [PMID: 24454709]

Christopher, R.; Edward, H.H.; Lawrence, L.C.; Simeon, B.; Probst, G.; Fitch-Bruhns, M.; Monteon, J.; Bermudez, A.; van der Horst, E.H.; Halcomb, R.L.; Jackson, D.Y. Antibody-Drug Conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm., 2015, 12(11), 3986-3998.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00432] [PMID: 26393951]

Svetlana, O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Wahl, A.F.; Meyer, D.L.; Senter, P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol., 2003, 21(7), 778-784.
[http://dx.doi.org/10.1038/nbt832] [PMID: 12778055]

Wagner-Rousset, E.; Janin-Bussat, M-C.; Beck, A. Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs, 2014, 6(1), 273-285.
[http://dx.doi.org/10.4161/mabs.26773] [PMID: 24135617]

Alicia, F.C. Investigational antibody- drug conjugates in clinical trials for the treatment of breast cancer. Expert Opin. Investig Drugs, 2021, 30(8), 789-795.
[http://dx.doi.org/10.1080/13543784.2021.1940950] [PMID: 34114911]

Ferraro, E.; Drago, J.Z.; Modi, S. Implementing antibody-drug conjugates(ADCs) in HER2-positive breast cancer: State of the art and future directions. Breast Cancer Res., 2021, 23(1), 84.
[http://dx.doi.org/10.1186/s13058-021-01459-y] [PMID: 34380530]

Jessica, R.; Owen, S.C. Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS J., 2015, 17(2), 339-351.
[http://dx.doi.org/10.1208/s12248-014-9710-8] [PMID: 25604608]

Heidi, L.; Cardarelli, P.M.; Deshpande, S.; Borzilleri, R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today, 2014, 19(7), 869-881.
[http://dx.doi.org/10.1016/j.drudis.2013.11.004] [PMID: 24239727]

Jefferis, R. Antibody therapeutics. Expert Opin. Biol. Ther., 2007, 7(9), 1401-1413.
[http://dx.doi.org/10.1517/14712598.7.9.1401] [PMID: 17727329]

Jochen, G. Isotype selection in antibody engineering. Nat. Biotechnol., 2007, 25(12), 1369-1372.
[http://dx.doi.org/10.1038/nbt1207-1369] [PMID: 18066027]

Eiger, D.; Agostinetto, E.; Saude-Conde, R.; De Azambuja, E. The exciting new field of her2-low breast cancer treatment. Cancers, 2021, 13(5), 1015.
[http://dx.doi.org/10.3390/cancers13051015] [PMID: 33804398]

Jain, N.; Smith, S.W.; Ghone, S.; Tomczuk, B. Current ADC linker chemistry. Pharm. Res., 2015, 32(11), 3526-3540.
[http://dx.doi.org/10.1007/s11095-015-1657-7] [PMID: 25759187]

Joshua, Z. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol., 2021, 18(6), 327-344.
[http://dx.doi.org/10.1038/s41571-021-00470-8] [PMID: 33558752]

Tsuchikama, K.; An, Z. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell, 2018, 9(1), 33-46.
[http://dx.doi.org/10.1007/s13238-016-0323-0] [PMID: 27743348]

Criscitiello, C.; Morganti, S.; Curigliano, G. Antibody-drug conjugates in solid tumors: A look into novel targets. J. Hematol. Oncol., 2021, 14(1), 20.
[http://dx.doi.org/10.1186/s13045-021-01035-z] [PMID: 33509252]

Wayne, C. Factors involved in the design of cytotoxic payloads for antibody-drug conjugates. In: Antibody-Drug Conjugates and Immunotoxins; Springer: New York, NY, 2013.

Juan, A.; Cimas, F.J.; Bravo, I.; Pandiella, A.; Ocaña, A.; Alonso-Moreno, C. Antibody conjugation of nanoparticle as therapeutics for breast cancer treatment. Int. J. Mol. Sci., 2020, 21(17), 6018.
[http://dx.doi.org/10.3390/ijms21176018]

Trail, P.A.; Dubowchik, G.M.; Lowinger, T.B. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol. Ther., 2018, 181, 126-142.
[http://dx.doi.org/10.1016/j.pharmthera.2017.07.013] [PMID: 28757155]

Aram, J.; Ibrahim, M.F.; Saifo, M.S. Antibody-drug conjugates used in breast cancers. J. Oncol., 2021, 2021, 9927433.
[http://dx.doi.org/10.1155/2021/9927433] [PMID: 34257655]

Rinnerthaler, G.; Gampenrieder, S.; Greil, R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int. J. Mol. Sci., 2019, 20(5), 1115.
[http://dx.doi.org/10.3390/ijms20051115] [PMID: 30841523]

Le Joncour, V.; Martins, A.; Puhka, M.; Isola, J.; Salmikangas, M.; Laakkonen, P.; Joensuu, H.; Barok, M. A novel anti- HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine. Mol. Cancer Ther., 2019, 18(10), 1721-1730.
[http://dx.doi.org/10.1158/1535-7163.MCT-19-0207] [PMID: 31292166]

Pondé, N.; Aftimos, P.; Piccart, M. Antibody-drug conjugates in breast cancer: A comprehensive review, current treatments. Curr. Treat. Options Oncol., 2019, 20(5), 37.
[http://dx.doi.org/10.1007/s11864-019-0633-6] [PMID: 30931493]

U.S. National Institutes of Health. anti-HER2 antibody-drug conjugate MEDI4276. 2020. Available from: https://www.cancer .gov/ publications/dictionaries/cancer-drug/def/anti-her2-vc0101-adc-pf-06804103

Altunay, B.; Morgenroth, A.; Beheshti, M.; Vogg, A.; Wong, N.C.L.; Ting, H.H.; Biersack, H-J.; Stickeler, E.; Mottaghy, F.M. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(5), 1371-1389.

Tymon-Rosario, J.; Bonazzoli, E.; Bellone, S.; Manzano, A.; Pelligra, S.; Guglielmi, A.; Gnutti, B.; Nagarkatti, N.; Zeybek, B.; Manara, P.; Zammataro, L.; Harold, J.; Mauricio, D.; Buza, N.; Hui, P.; Altwerger, G.; Menderes, G.; Ratner, E.; Clark, M.; Andikyan, V.; Huang, G.S.; Silasi, D-A.; Azodi, M.; Schwartz, P.E.; Santin, A.D. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecol. Oncol., 2021, 163(2), 334-341.

Lee, B.; Park, M-H.; Byeon, J-J.; Shin, S-H.; Choi, J.; Park, Y.; Park, Y-H.; Chae, J.; Shin, Y.G. Quantification of an antibody-conjugated drug in fat plasma by an affinity capture LC-MS/MS method for a novel prenyl transferase-mediated site-specific antibody–drug conjugate. Molecules, 2020, 25(7), 1515.
[http://dx.doi.org/10.3390/molecules25071515]

Deeks, E. Disitamab vedotin: First approval. Drugs, 2021, 81(16), 1929-1935.

Review, A.D.C. Hertuzumab vedotin;. 2020. Available from: https://www.adcreview.com/drugmap/hertuzumab-vedotin/

Li, Hongwen; Yu, Chao; Jiang, Jing; Huang, Changjiang; Yao, Xuejing; Xu, Qiaoyu; Yu, Fang; Lou, Liguang; Fang, Jianmin An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer Biol. Ther., 2016, 17(4), 346-354.

Faria, M.; Peay, M.; Lam, B.; Ma, E.; Yuan, M.; Waldron, M.; Mylott, W.R., Jr; Liang, M.; Rosenbaum, A.I. Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized antibody against HER-2. Antibodies, 2019, 8(1), 11.

Avilés, P.; Domínguez, J.M.; Guillén, M.J.; Muñoz-Alonso, M.J.; Mateo, C.; Rodriguez-Acebes, R.; Molina-Guijarro, J.M.; Francesch, A.; Martínez-Leal, J.F.; Munt, S.; Galmarini, C.M.; Cuevas, C. MI130004, a novel antibody-drug conjugate combining trastuzumab with a molecule of marine origin, shows outstanding in vivo activity against HER2-expressing tumors. Mol. Cancer Ther., 2018, 17(4), 786-794.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0795] [PMID: 29440297]

Conjugates, A.R.J.A-D. MI130004. 2020. Available from: https://www.adcreview.com/drugmap/mi130004/

Xu, Z.; Guo, D.; Jiang, Z.; Tong, Rongsheng; Jiang, Peidu; Bai, Lan; Chen, Lu; Zhu, Yuxuan; Guo, Chun; Shi, Jianyou; Yu, Dongke Novel HER2-targeting antibody- drug conjugates of trastuzumab beyond T-DM1 in breast cancer: Trastuzumab deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur. J. Med. Chem., 2019, 183, 111682.

Conjugates, A.R.J.A-D. Trastuzumab duocarmazine |SYD985 | Trastuzumab vc- seco-DUBA. 2020. Available from: https://www.adcreview.com/drugmap/trastuzumabduocarmazinesyd985/

Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res., 2020, 22(1), 61.
[http://dx.doi.org/10.1186/s13058-020-01296-5] [PMID: 32517735]

Monoclonal antibody therapy in treating women with locally advanced or metastatic breast cancer previously treated with combination chemotherapy. NCT00066547, , 2003.

Clinical study of recombinant anti-her2 humanized monoclonal antibody for injection. NCT04170595,, 2019.

Atezolizumab, cobimetinib, and eribulin in treating patients with chemotherapy resistant metastatic inflammatory breast cancer. NCT03202316, , 2017.

Testing the drug atezolizumab or placebo with usual therapy in first-line HER2-positive metastatic breast cancer. NCT03199885, , 2017.

Inetetamab plus cyclophosphamide metronomic chemotherapy plus aromatase inhibitor in metastatic HER2+/HR+ breast cancer (Increase). NCT04941885, , 2021.

Carboplatin and paclitaxel with or without panitumumab in treating patients with invasive triple negative breast cancer. NCT02876107, , 2016.

Olaparib in combination with either durvalumab, selumetinib, or capivasertib or ceralasertib alone in treating patients with metastatic triple negative breast cancer. NCT03801369, , 2023.

Dong, W.; Shi, J.; Yuan, T.; Qi, B.; Yu, J.; Dai, J.; He, L. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. Eur. J. Med. Chem., 2019, 167, 583-593.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.017] [PMID: 30822636]

Bardia, A.; Mayer, I.A.; Vahdat, L.T.; Tolaney, S.M.; Isakoff, S.J.; Diamond, J.R.; O’Shaughnessy, J.; Moroose, R.L.; Santin, A.D.; Abramson, V.G.; Shah, N.C.; Rugo, H.S.; Goldenberg, D.M.; Sweidan, A.M.; Iannone, R.; Washkowitz, S.; Sharkey, R.M.; Wegener, W.A.; Kalinsky, K. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med., 2019, 380(8), 741-751.
[http://dx.doi.org/10.1056/NEJMoa1814213] [PMID: 30786188]

Nagayama, A.; Vidula, N; Ellisen, L; Bardia, A Novel antibody-drug conjugates for triple negative breast cancer. Ther. Adv. Med. Oncol., 2020, 12, 1758835920915980.
[http://dx.doi.org/10.1177/1758835920915980] [PMID: 32426047]

Sussman, D.; Smith, L.M.; Anderson, M.E.; Duniho, S.; Hunter, J.H.; Kostner, H.; Miyamoto, J.B.; Nesterova, A.; Westendorf, L.; Van Epps, H.A.; Whiting, N.; Benjamin, D.R. SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol. Cancer Ther., 2014, 13(12), 2991-3000.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0896] [PMID: 25253783]

Hashimoto, Y.; Koyama, K.; Kamai, Y.; Hirotani, K.; Ogitani, Y.; Zembutsu, A.; Abe, M.; Kaneda, Y.; Maeda, N.; Shiose, Y.; Iguchi, T.; Ishizaka, T.; Karibe, T.; Hayakawa, I.; Morita, K.; Nakada, T.; Nomura, T.; Wakita, K.; Kagari, T.; Abe, Y.; Murakami, M.; Ueno, S.; Agatsuma, T. A novel HER3- targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin. Cancer Res., 2019, 25(23), 7151-7161.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1745] [PMID: 31471314]

Bayerlová, M.; Menck, K.; Klemm, F.; Wolff, A.; Pukrop, T.; Binder, C.; Beißbarth, T.; Bleckmann, A. Ror2 signaling and its relevance in breast cancer progression. Front. Oncol., 2017, 7, 135.
[http://dx.doi.org/10.3389/fonc.2017.00135] [PMID: 28695110]

Trombe, M.; Caron, A.; Tellier, A.; Carrez, C.; Guérif, S.; Clavier, S.; Karst, N.; Saarinen, J.; Satomaa, T.; Pitkänen, V.; Aitio, O.; Heiskanen, A.; Fassan, M.; Pinkas, J.; Baffa, R.; Blanc, V.; Nicolazzi, C. Abstract 235: Preclinical activity of an antibody drug conjugate targeting tumor specificmuc1 structural peptide-glycotope. Cancer Res., 2019, 79(13_Supplement), 235.
[http://dx.doi.org/10.1158/1538-7445.AM2019-235]

Fu, Z.; Li, S.; Han, S.; Shi, C.; Zhang, Y. Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther., 2022, 7(1), 93.
[http://dx.doi.org/10.1038/s41392-022-00947-7] [PMID: 35318309]

Mercogliano, M.F.; Bruni, S.; Mauro, F.L.; Schillaci, R. Emerging targeted therapies for HER2-positive breast cancer. Cancers, 2023, 15(7), 1987.
[http://dx.doi.org/10.3390/cancers15071987] [PMID: 37046648]

Swain, S.M.; Miles, D.; Kim, S.B.; Im, Y.H.; Im, S.A.; Semiglazov, V.; Ciruelos, E.; Schneeweiss, A.; Loi, S.; Monturus, E.; Clark, E.; Knott, A.; Restuccia, E.; Benyunes, M.C.; Cortés, J.; Agajanian, R.; Ahmad, R.; Aktas, B.; Alencar, V.H.; Amadori, D.; Andrade, J.; André Franke, F.; Angiolini, C.; Aogi, K.; Armor, J.; Arpornwirat, W.; Assersohn, L.; Audeh, W.; Aulitzky, W.; Azevedo, S.; Bartoli, M.A.; Batista Lopez, N.; Bianconi, M.; Biganzoli, L.; Birhiray, R.; Bitina, M.; Blachy, R.; Blackwell, K.; Blanchard, R.; Blanchet, P.; Boiangiu, I.; Bower, B.; Brezden-Masley, C.; Brufsky, A.; Budde, L.; Caguioa, P.; Calvo, L.; Campone, M.; Carroll, R.R.; Castro, H.; Chan, V.; Charu, V.; Cinieri, S.; Clemens, M.; Conejo, E.A.; Côrtes, E.; Coudert, B.; Cronemberger, E.; Cubero, D.; Dakhil, S.; Daniel, B.; Davidson, N.; De Fatima Gaui, M.; De La Cruz, S.; Del Pilar, M.; Delgado, G.; Ellerton, J.A.; Estuardo, C.; Fehrenbacher, L.; Ferrero, J-M.; Flynn, P.J.; Foszczynska-Kloda, M.; Franco, S.; Fujii, H.; Gallagher, C.; Gamucci, T.; Giacomi, N.; Gil I Gil, M.; Gonzalez Martin, A.; Gorbunova, V.; Gotovkin, E.; Green, N.; Grincuka, E.; Grischke, E-M.; Hansen, V.; Hargis, J.; Hauschild, M.; Hegg, R.; Hendricks, C.; Hermann, R.; Hoff, P.; Horiguchi, J.; Hornedo Muguiro, J.; Iacobelli, S.; Inoue, K.; Ismael, G.; Itoh, Y.; Iwata, D.H.; Jendiroba, D.; Jochim, R.; Jones, A.; Just, M.; Kallab, A.; Karwal, M.; Kashiwaba, M.; Kato, G.; Kaufman, P.A.; Kellokumpu-Lehtinen, P.; Kirsch, A.; Kiselev, I.; Klein, P.; Kohno, N.; Kopp, M.; Kostovska-Maneva, L.; Kotliar, M.; Kudaba, I.; Kümmel, S.; Kuroi, K.; Lacava, J.; Latini, L.; Lee, S.C.; Lichinitser, M.; Lobo, C.; Maintz, C.; Maneecahvakajorn, J.; Marmé, A.; Martinez, G.; Masuda, N.; Matwiejuk, M.; Merculov, V.; Michaelson, R.; Miguel, L.; Monroy, H.; Montemurro, F.; Morales, S.; Moura, R.; Mueller, V.; Mulatero, C.; Nakagami, K.; Nakayama, T.; Neidhart, J.; Nguyen, A.; Nishimura, R.; Ogata, H.; O’reilly, S.; O’rourke, T.; Otero Reye, D.; Ouyang, X.; Patel, R.; Patel, T.; Pedrini, J.L.; Pereira, R.; Perez, A.; Peterson, C.; Pienkowski, T.; Pinczowski, H.; Polikoff, J.; Polkowski, W.; Price, P.E.; Prill, S.; Priou, F.; Purkalne, G.; Pyrhoenen, S.; Quackenbush, R.; Rai, Y.; Ribelles, N.; Ro, J.; Robinson, A.; Robles, R.; Rodriguez, G.; Roman, L.; Saji, S.; Sanchez-Rovira, P.; Sato, N.; Schmidt, M.; Schumacher, C.; Senecal, F.; Sharma, P.; Shen, Z.; Shirinkin, V.; Simoncini, E.; Sirisinha, T.; Smith, R.; Sohn, J-H.; Soldic, Z.; Soria, T.; Spicer, D.; Srimuninnimit, V.; Sriuranpong, V.; Staroslawska, E.; Stefanovski, P.; Sunpaweravong, P.; Taguchi, J.; Takeda, K.; Tellez-Trevilla, G.; Thomas, R.; Thomssen, C.; Toache, Z.; Tokuda, Y.; Tomczak, P.; Tosello, C.; Tsugawa, K.; Tudtud, D.; Ueno, T.; Van Eyll, B.; Varela, M.; Vasev, N.; Vrbanec, D.; Wang, X.; Wang, L.; Watanabe, J.; Waterhouse, D.; Wesenberg, B.; Wheatley, D.; Wong, Z.W.; Yadav, S.; Yadav, S.; Yardley, D.; Yau, T-K.; Yeo, W.; Ying, C.; Youn Oh, D. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2020, 21(4), 519-530.
[http://dx.doi.org/10.1016/S1470-2045(19)30863-0] [PMID: 32171426]

Abuhelwa, Z.; Alloghbi, A.; Nagasaka, M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat. Rev., 2022, 106, 102393.
[http://dx.doi.org/10.1016/j.ctrv.2022.102393] [PMID: 35472631]

Jeon, E.J.; Han, J.H.; Seo, Y.; Koh, E.M.; Han, K.H.; Hwang, K.; Jung, K.J. Implementation of systematic bioanalysis of antibody–drug conjugates for preclinical pharmacokinetic study of ado-trastuzumab emtansine (T-DM1) in rats. Pharmaceutics, 2023, 15(3), 756.
[http://dx.doi.org/10.3390/pharmaceutics15030756] [PMID: 36986616]

Liu, T.; Tao, Y.; Xia, X.; Zhang, Y.; Deng, R.; Wang, Y. Analytical tools for antibody-drug conjugates: From in vitro to in vivo. Trends Analyt. Chem., 2022, 152, 116621.
[http://dx.doi.org/10.1016/j.trac.2022.116621]

Fumagalli, C.; Ranghiero, A.; Gandini, S.; Corso, F.; Taormina, S.; De Camilli, E.; Rappa, A.; Vacirca, D.; viale, G.; Guerini-Rocco, E.; Barberis, M. Inter-tumor genomic heterogeneity of breast cancers: Comprehensive genomic profile of primary early breast cancers and relapses. Breast Cancer Res., 2020, 22(1), 107.
[http://dx.doi.org/10.1186/s13058-020-01345-z] [PMID: 33059724]

Najjar, S.; Allison, K.H. Updates on breast biomarkers. Virchows Arch., 2022, 480(1), 163-176.
[http://dx.doi.org/10.1007/s00428-022-03267-x] [PMID: 35029776]

Cruz, E.; Kayser, V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019, 13, 33-51.
[http://dx.doi.org/10.2147/BTT.S166310] [PMID: 31118560]

Redig, A.J.; McAllister, S.S. Breast cancer as a systemic disease: A view of metastasis. J. Intern. Med., 2013, 274(2), 113-126.
[http://dx.doi.org/10.1111/joim.12084] [PMID: 23844915]